24/7 Market News Snapshot 02 April, 2025 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

April 2, 2025

DENVER, Colo., 02 April, 2025 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is witnessing a significant surge in its stock price, currently trading at $1.060 in pre-market activities, indicating a robust increase of approximately 8.75% from the previous close of $0.975. This uptick is accompanied by impressive trading volume, with 2.47 million shares exchanged, suggesting heightened investor interest. The stock’s technical indicators are showing signs of breaking through critical resistance levels, which bodes well for potential future gains. Investors are advised to closely monitor price movements and volume trends as they evaluate the stock within the context of broader market conditions.

In parallel to the stock’s performance, Hoth Therapeutics has announced exciting preclinical results for its lead candidate, HT-ALZ, which targets the urgent issue of Alzheimer’s disease (AD). Leveraging a previously FDA-approved NK-1 receptor antagonist, HT-ALZ has demonstrated significant cognitive and behavioral enhancements in APP/PS1 mouse models. Chronic treatment with HT-ALZ showed marked improvements in memory retention, reduced anxiety-like behaviors, and better sensorimotor gating, all while preserving motor function.

The treatment has also led to a substantial reduction in GFAP-positive reactive astrocytes, known contributors to neuroinflammation associated with cognitive decline in AD. CEO Robb Knie highlighted the groundbreaking nature of these findings, stating, “Our results emphasize a transformative therapeutic approach for Alzheimer’s by addressing neuroinflammation—an often underexplored area by conventional therapies focused solely on amyloid plaques.”

HT-ALZ exhibited rapid therapeutic effects, including a notable 15% reduction in brain interstitial fluid Aβ levels after acute treatment, underscoring its dual capability in addressing symptoms and pathology. With favorable oral bioavailability and a promising safety profile, HT-ALZ is positioned for advancement in clinical development, representing Hoth Therapeutics’ commitment to improving treatments for early-stage Alzheimer’s disease and enhancing patients’ quality of life.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.